Jones Financial Companies
ENTA icon

Jones Financial Companies’s Enanta Pharmaceuticals ENTA Stock Holding History

Jones Financial Companies’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60
Closed -$474 – 4461
2025
Q3 		$474 Buy
+60
New +$479 ﹤0.01% 4042

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jones Financial Companies's ENTA Position: Q4 2025 in Review

Jones Financial Companies sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 60 shares — an estimated $474 sold.

Jones Financial Companies first reported a position in ENTA in Q3 2025 and held it in 1 quarter. The position peaked at $474 in Q3 2025. 132 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Jones Financial Companies reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jones Financial Companies sold 60 Enanta Pharmaceuticals shares in Q4 2025, an estimated $474.
  • Jones Financial Companies first reported a position in Enanta Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Jones Financial Companies's Enanta Pharmaceuticals position peaked at $474 in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Jones Financial Companies's 13F filing for Q4 2025, filed 17 Feb 2026.